• Pfizer presented Phase 2 results for tilrekimig in moderate-to-severe atopic dermatitis at the EADV congress.
• The study met its main goal, showing more patients reached strong skin clearance than placebo.
• Safety looked comparable to placebo, with no serious drug-related events reported.
• Pfizer has started Phase 3 trials in atopic dermatitis and asthma, with a Phase 2b/3 study underway in COPD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610010230BIZWIRE_USPR_____20260930_BW032966) on October 01, 2026, and is solely responsible for the information contained therein.